Cargando…

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. The aim of this study was conducted a meta-analysis to assess the efficacy and safety of PD-1/PD-L1 inhibitors in patients with unresectable hepatocellular carcinoma (uHC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Linyan, Su, Junwei, Qiu, Wenqi, Jin, Xuehang, Qiu, Yunqing, Yu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014721/
https://www.ncbi.nlm.nih.gov/pubmed/35418272
http://dx.doi.org/10.1177/10732748221092924
_version_ 1784688243520831488
author Zeng, Linyan
Su, Junwei
Qiu, Wenqi
Jin, Xuehang
Qiu, Yunqing
Yu, Wei
author_facet Zeng, Linyan
Su, Junwei
Qiu, Wenqi
Jin, Xuehang
Qiu, Yunqing
Yu, Wei
author_sort Zeng, Linyan
collection PubMed
description Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. The aim of this study was conducted a meta-analysis to assess the efficacy and safety of PD-1/PD-L1 inhibitors in patients with unresectable hepatocellular carcinoma (uHCC). A total of 1657 patients were included. The completed phase III trials with details data, such as overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects (AEs) were included. The pooled hazard ratio (HR) of OS and PFS were .75 (95% CI: .61–.92) and .74 (95% CI: .56–.97) with heterogeneity between PD-1/PD-L1 inhibitors groups and control groups. Sensitivity analysis revealed IMbrave-150 could be the most important factor of heterogeneity for OS, while CheckMate-459 was the main fact of heterogeneity for PFS. In addition, the relative risk (RR) of ORR and DCR were 2.43 (95% CI: 1.80–3.26) and 1.26 (95% CI: 1.11–1.43) with low heterogeneity in PD-1/PD-L1 inhibitors groups. The therapeutic effect of PD-1/PD-L1 inhibitors was better in females, Asia without Japan, BCLC status C and infected hepatitis groups. The RR of AEs from any cause and serious adverse events (SAEs) for patients receiving PD-1/PD-L1 inhibitors were 1.03 (95% CI: .93–1.13) and 1.13 (95% CI: .89–1.44), respectively. Pruritus was the most common AEs reported in 10% of patients or more (RR = 1.69, 95% CI: 1.33–2.15). In conclusion, PD-L1 inhibitor combined with anti-VEGF antibody could improve the prognosis of patients with uHCC. However, caution should be taken for AEs during patients receiving PD-1/PD-L1 inhibitors.
format Online
Article
Text
id pubmed-9014721
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90147212022-04-19 Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials Zeng, Linyan Su, Junwei Qiu, Wenqi Jin, Xuehang Qiu, Yunqing Yu, Wei Cancer Control Original Research Article Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. The aim of this study was conducted a meta-analysis to assess the efficacy and safety of PD-1/PD-L1 inhibitors in patients with unresectable hepatocellular carcinoma (uHCC). A total of 1657 patients were included. The completed phase III trials with details data, such as overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects (AEs) were included. The pooled hazard ratio (HR) of OS and PFS were .75 (95% CI: .61–.92) and .74 (95% CI: .56–.97) with heterogeneity between PD-1/PD-L1 inhibitors groups and control groups. Sensitivity analysis revealed IMbrave-150 could be the most important factor of heterogeneity for OS, while CheckMate-459 was the main fact of heterogeneity for PFS. In addition, the relative risk (RR) of ORR and DCR were 2.43 (95% CI: 1.80–3.26) and 1.26 (95% CI: 1.11–1.43) with low heterogeneity in PD-1/PD-L1 inhibitors groups. The therapeutic effect of PD-1/PD-L1 inhibitors was better in females, Asia without Japan, BCLC status C and infected hepatitis groups. The RR of AEs from any cause and serious adverse events (SAEs) for patients receiving PD-1/PD-L1 inhibitors were 1.03 (95% CI: .93–1.13) and 1.13 (95% CI: .89–1.44), respectively. Pruritus was the most common AEs reported in 10% of patients or more (RR = 1.69, 95% CI: 1.33–2.15). In conclusion, PD-L1 inhibitor combined with anti-VEGF antibody could improve the prognosis of patients with uHCC. However, caution should be taken for AEs during patients receiving PD-1/PD-L1 inhibitors. SAGE Publications 2022-04-14 /pmc/articles/PMC9014721/ /pubmed/35418272 http://dx.doi.org/10.1177/10732748221092924 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Zeng, Linyan
Su, Junwei
Qiu, Wenqi
Jin, Xuehang
Qiu, Yunqing
Yu, Wei
Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
title Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
title_full Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
title_fullStr Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
title_full_unstemmed Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
title_short Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
title_sort survival outcomes and safety of programmed cell death/programmed cell death ligand 1 inhibitors for unresectable hepatocellular carcinoma: result from phase iii trials
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014721/
https://www.ncbi.nlm.nih.gov/pubmed/35418272
http://dx.doi.org/10.1177/10732748221092924
work_keys_str_mv AT zenglinyan survivaloutcomesandsafetyofprogrammedcelldeathprogrammedcelldeathligand1inhibitorsforunresectablehepatocellularcarcinomaresultfromphaseiiitrials
AT sujunwei survivaloutcomesandsafetyofprogrammedcelldeathprogrammedcelldeathligand1inhibitorsforunresectablehepatocellularcarcinomaresultfromphaseiiitrials
AT qiuwenqi survivaloutcomesandsafetyofprogrammedcelldeathprogrammedcelldeathligand1inhibitorsforunresectablehepatocellularcarcinomaresultfromphaseiiitrials
AT jinxuehang survivaloutcomesandsafetyofprogrammedcelldeathprogrammedcelldeathligand1inhibitorsforunresectablehepatocellularcarcinomaresultfromphaseiiitrials
AT qiuyunqing survivaloutcomesandsafetyofprogrammedcelldeathprogrammedcelldeathligand1inhibitorsforunresectablehepatocellularcarcinomaresultfromphaseiiitrials
AT yuwei survivaloutcomesandsafetyofprogrammedcelldeathprogrammedcelldeathligand1inhibitorsforunresectablehepatocellularcarcinomaresultfromphaseiiitrials